膀胱鳞状细胞癌治疗策略的比较有效性研究
基于美国国家癌症数据库的回顾性研究,纳入828例临床T2/3N0M0纯鳞状细胞膀胱癌患者,比较根治性膀胱切除术联合或不联合围手术期化疗与其他治疗方式的总体生存。加权回归显示,根治性膀胱切除术联合或不联合围手术期化疗的生存显著优于化疗、放疗或放化疗;作者认为根治性膀胱切除术联合或不联合化疗应作为该病的 upfront 治疗。
要点
- 根治性膀胱切除术联合或不联合围手术期化疗的总体生存显著优于其他治疗方式。
- 与单纯根治性膀胱切除术相比,单纯化疗、单纯放疗和放化疗的死亡风险比分别为2.43、4.78和1.61。
- 根治性膀胱切除术联合新辅助或辅助化疗与单纯根治性膀胱切除术的生存无显著差异。
核心结论
- 根治性膀胱切除术联合或不联合围手术期化疗应被视为膀胱鳞状细胞癌的 upfront 治疗。
- 根治性膀胱切除术联合或不联合化疗应作为该病的标准治疗。
研究设计与样本
- 回顾性研究,查询美国国家癌症数据库,纳入828例局限期肌层浸润性纯鳞状细胞膀胱癌(临床分期T2/3N0M0)患者。
- 治疗分组包括:单纯根治性膀胱切除术465例,新辅助化疗+根治性膀胱切除术53例,根治性膀胱切除术+辅助化疗48例,单纯化疗72例,单纯放疗88例,放化疗102例。
- 采用多项倾向评分方法创建治疗权重,并应用于加权Cox比例风险模型评估总体生存,调整年龄、TNM临床分期、Charlson合并症指数、种族、性别及机构与县水平变量。
主要发现
- 加权回归显示,根治性膀胱切除术联合或不联合围手术期化疗的总体生存显著优于其他治疗方式。
- 与单纯根治性膀胱切除术相比,单纯化疗的死亡风险比为2.43(95%CI 1.65-3.59),单纯放疗为4.78(95%CI 3.33-6.86),放化疗为1.61(95%CI 1.16-2.25),均p<0.005。
- 根治性膀胱切除术联合新辅助化疗与单纯根治性膀胱切除术相比,死亡风险比为1.33(95%CI 0.89-1.98)。
- 根治性膀胱切除术联合辅助化疗与单纯根治性膀胱切除术相比,死亡风险比为1.11(95%CI 0.66-1.85)。
临床怎么用
- 作者认为,根治性膀胱切除术联合或不联合围手术期化疗应被视为膀胱鳞状细胞癌的 upfront 治疗。
- 作者认为,根治性膀胱切除术联合或不联合化疗应作为该病的标准治疗。
局限性
- 这些发现受限于小样本量和研究的回顾性性质。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While there is established evidence supporting the use of radical cystectomy (RC) and perioperative chemotherapy for muscle-invasive urothelial carcinoma of the bladder, such evidence does not exist for squamous cell carcinoma. OBJECTIVE: We present the largest study to date of patients with squamous cell carcinoma and compare the effectiveness of possible treatment regimens for overall survival. DESIGN, SETTING, AND PARTICIPANTS: The National Cancer Data Base was queried for cases of localized, muscle-invasive pure squamous cell bladder cancer, classified as clinical stage T2/3N0M0. Permutations of surgery (RC), chemotherapy, and external beam radiation were selected. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A multinomial propensity score method was used to create treatment weights based on clinical characteristics predicting the probability of treatment receipt. These were then applied in weighted Cox proportional hazards models to assess the comparative effectiveness of treatments for overall survival, adjusting for age, TNM clinical stage, Charlson comorbidity index, race, sex, and facility and county level variables. RESULTS AND LIMITATIONS: A total of 828 cases were included, comprising 465 RC alone, 53 neoadjuvant chemotherapy+RC, 48 RC+adjuvant chemotherapy, 72 chemotherapy alone, 88 radiation alone, and 102 chemoradiation cases. On weighted regression, RC treatment with or without perioperative chemotherapy was associated with significantly better overall survival compared to the other treatment modalities; chemotherapy alone, radiation alone, and chemoradiation were associated with a hazard ratio (HR) of death of 2.43 (95% confidence interval [CI] 1.65-3.59), 4.78 (95% CI 3.33-6.86), and 1.61 (95% CI 1.16-2.25), respectively, compared to RC alone (all p<0.005). A combination of RC and neoadjuvant chemotherapy was comparable to RC alone, with HR of death 1.33 (95% CI 0.89-1.98). The combination of RC and adjuvant chemotherapy was also similar to RC alone (HR 1.11, 95% CI 0.66-1.85). These findings are limited by small numbers and the retrospective nature of the study. CONCLUSIONS: RC with or without perioperative chemotherapy should be considered an upfront therapy for squamous cell carcinoma of the bladder. PATIENT SUMMARY: Using a national database, we compared treatments for muscle-invasive squamous cell bladder cancer. Patients undergoing radical cystectomy with or without chemotherapy had longer survival. Radical cystectomy with or without chemotherapy should be the standard of care for this disease.
引用
- Stensland KD, Zaid H, Broadwin M, et al. Comparative Effectiveness of Treatment Strategies for Squamous Cell Carcinoma of the Bladder. Eur Urol Oncol. 2018. PMID: 31411987. doi:10.1016/j.euo.2018.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。